title: No effect of tocolytic therapy with atosiban on maternal serum interleukin-6 and tumor necrosis factor-alpha in threatened preterm labor.
abstract: OBJECTIVE
  We aimed to evaluate the effect of intravenous administration of tocolytic therapy with an oxytocin antagonist drug (atosiban) on maternal serum interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) levels in women with threatened preterm labor.
  
  
  METHODS
  The study population consisted of 46 women with a singleton pregnancy admitted to our department with a diagnosis of threatened preterm labor at between 26 and 34 weeks of gestation. Atosiban was administered to all women. Nine women (group A) progressed to delivery within 48 hours of admission. The remaining 37 women were divided in two groups: group B consisted of 16 women who remained undelivered at 48 hours but experienced delivery within 7 days and group C consisted of 21 women who did not deliver within the next 7 days. Maternal serum IL-6 and TNF-alpha levels were assessed in duplicate by a high sensitivity ELISA kit on patient admission and again at the end of treatment with atosiban (36 hours post-admission).
  
  
  RESULTS
  Serum IL-6 and TNF-alpha concentrations on admission were significantly higher in group A compared to those found in group B (p = 0.01) and group C (p = 0.04). Comparisons of serum IL-6 values on admission and at 36 hours after the initiation of atosiban treatment were comparable in group A (p = 0.95), group B (p = 0.39), and group C (p = 0.79). Similarly serum TNF-alpha levels on admission were not significantly different compared to those at the end of treatment in all groups (p = 0.85 for group A, p = 0.45 for group B, and p = 0.21 for group C).
  
  
  CONCLUSIONS
  No effect of tocolytic therapy with atosiban was observed on serum IL-6 and TNF-alpha levels in women with threatened preterm labor.
authors.affiliation: Second Department of Obstetrics and Gynecology, University of Athens, Aretaieion Hospital, Athens, Greece. nikolasvitoratos@yahoo.gr
authors.forename: N
authors.initials: N
authors.lastname: Vitoratos
authors.forename: A
authors.initials: A
authors.lastname: Kountouris
authors.forename: E
authors.initials: E
authors.lastname: Makrakis
authors.forename: K
authors.initials: K
authors.lastname: Papadias
authors.forename: G
authors.initials: G
authors.lastname: Creatsas
mesh_terms: D000328:Adult; D005260:Female; D006801:Humans; D015850:Interleukin-6 / Q000097:blood*; D007752:Obstetric Labor, Premature / Q000097:blood / Q000188:drug therapy*; D011247:Pregnancy; D015149:Tocolytic Agents / Q000494:pharmacology*; D014409:Tumor Necrosis Factor-alpha / Q000097:blood / Q000187:drug effects*; D014668:Vasotocin / Q000031:analogs & derivatives* / Q000494:pharmacology
chemical_list: D015850:Interleukin-6; D015149:Tocolytic Agents; D014409:Tumor Necrosis Factor-alpha; C047046:atosiban; D014668:Vasotocin